Wei Xiong

Wei Xiong

Auto-generated profile, based on publicly available information

Wei Xiong

Department of Endocrinology Wuhan Red Cross Hospital Wuhan Hubei China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
JLJinghong Li
Jinghong Li
QWQi Wei
Qi Wei
KMKaren C. McCowen
Karen C. McCowen
WXWei Xiong
Wei Xiong
JLJiao Liu
Jiao Liu
WLWillis X Li
Willis X Li
Aims: Type 2 diabetes mellitus (T2DM) is a strong risk factor for complications of coronavirus disease 2019 (COVID‐19). The effect of T2DM medications on COVID‐19 outcomes remains unclear. In a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID‐19 in Wuhan, we have previously found that metformin use prior to hospitalization is associated with reduced mortality. The current study aims to investigate the effects of inpatient use of T2DM medications, including metformin, acarbose, insulin and sulfonylureas, on the mortality of COVID‐19 patients with T2DM during hospitalization.Methods: We continue to carry out a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID‐19 and treated with different combinations of diabetes medications.Results: We found that patients using metformin (p = .02) and acarbose (p = .04), alone or both together (p = .03), after admission were significantly more likely to survive than those who did not use either metformin or acarbose. 37 patients continued to take metformin after admission and 35 (94.6%) survived. Among the 57 patients who used acarbose after admission, 52 survived (91.2%). A total of 20 patients used both metformin and acarbose, while 57 used neither. Of the 20 dual‐use patients, 19 (95.0%) survived.Conclusion: Our analyses suggest that inpatient use of metformin and acarbose together or alone during hospitalization should be studied in randomized trials.

1 June 2007 in Chinese Medical Journal
Verified
Journal Article
Open access
ZLZhang Li
Zhang Li
PWPing Wu
Ping Wu
SJShengwei Jin
Shengwei Jin
PYPing Yuan
Ping Yuan
JWJingyuan Wan
Jingyuan Wan
DYDu-Yun Ye
Du-Yun Ye
Lipoxins (LXs), endogenous anti-inflammatory and pro-resolving eicosanoids generated during various inflammatory conditions, have novel immunomodulatory properties. Because dendritic cells (DCs) play crucial roles in the initiation and maintenance of immune response, we determined whether LXs could modulate the maturation process of DCs and investigated the effects of lipoxin A4 (LXA4) on lipopolysaccharide (LPS)-induced differentiation of RAW264.7 cells into dendritic-like cells. RAW264.7 cells were cultured in vitro with 1 μg/ml LPS in the absence or presence of LXA4 for 24 hours, and cellular surface markers (MHC-II, CD80 (B7–1), CD86(B7–2)) were measured by flow cytometry (FCM). Mixed lymphocyte reaction was performed to evaluate the allostimulatory activity. Cytoplastic IκB degradation and nuclear factor kappa B (NF-κB) translocation were detected by Western blotting. Luciferase reporter plasmid was transiently transfected into RAW264.7 cells, and luciferase activity was determined to measure the transcriptional activity of NF-κB. LXA4 reduced the ratio of LPS-treated RAW264.7 cells to DCs with morphological characteristics and inhibited the expression of MHC II. LPS-induced up-regulation of CD86 was moderately suppressed by LXA4 but no obvious change of CD80 was observed. Moreover, LXA4 weakened the allostimulatory activity of LPS-treated RAW264.7 cells. These alterations of LPS+LXA4-treated cells were associated with a marked inhibition of IκB degradation, NF-κB translocation and then the transcriptional activity of NF-κB. LXA4 negatively regulates LPS-induced differentiation of RAW264.7 cells into dendritic-like cells.This activity reveals an undescribed mechanism of LXA4 to prevent excessive and sustained immune reaction by regulating maturation of DCs. Chin Med J 2007;120(11):981–987

9 June 2012 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
ZZZhengguo Zhang
Zhengguo Zhang
KLKuanxin Li
Kuanxin Li
XZXiaomei Zhang
Xiaomei Zhang
ZFZhong Fang
Zhong Fang
WXWei Xiong
Wei Xiong
FLFeng Li
Feng Li